



Post Partum Depression

PPD is an unpredictable and debilitating psychiatric condition affecting 1 in 5 women¹. **mynd Diagnostics** intends to initiate clinical studies to examine blood samples from women susceptible to PPD and aims to solidify evidence that contributes to the necessary development of the **MAP** biomarker in early diagnostic protocols.



MAP CLINICAL DATA IS EXPECTED BE SUBMITTED TO THE FDA IN Q2 2022 FOR APPROVAL AS A QUALIFIED PPD DIAGNOSTIC INSTRUMENT

Today, there is **no single diagnostic test** that can determine if a person has Post Partum Depression

- Current PPD screening tools are expensive, time consuming and difficult to interpret
- Identifying women who may be at risk of PPD with heightened levels of neuroinflammation in pregnancy or postpartum, presents a novel opportunity to help negate the chance of a PPD crisis.
- Exploring a Contract Research Agreement that will conduct diagnostic trials to validate the MAP biomarker as an objective diagnostic and monitoring tool for PPD

(1) STATS CITED